Mode
Text Size
Log in / Sign up
Phase 2 N=124 Treatment

Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)

Medium and Lower Rectal Cancer

Enrolled (actual)
124
Serious AEs
54.0%
Results posted
Aug 2021
Primary outcome: Primary: Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA — 1 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) (Procedure); Colo-anal anastomosis (CAA) (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Institut Bergonié
Primary completion
May 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA
1
SECONDARY
Stomata Bypass (Preventive or Therapeutic)
2; 49; 3; 3; 6; 8
SECONDARY
Post-operative Morbidity
13; 10
SECONDARY
Postoperative Mortality
0; 0
SECONDARY
Progression-free Survival
76.5; 92.2; 63.3; 81.3
SECONDARY
Number of Participants With Anal Incontinence at 6 Months
25; 32
SECONDARY
Number of Participants With Anal Incontinence at 12 Months
15; 36
SECONDARY
Number of Participants With Anal Incontinence at 24 Months
11; 29
SECONDARY
Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among CAA
5

Summary

Hypothesis: In France, approximately 12,000 new rectal cancers are diagnosed each year. Frequency is one and a half times higher in men than in women. The average age of diagnosis is 65. Unlike colon cancer, technical management remains challenging with unresolved operating difficulties. Morbidity of surgical procedures remains high with a very large number of preventive or curative stoma derivations. Reference in surgical treatment is total excision of the rectum and its mesentery, followed by continuity restoration by immediate coloanal anastomosis (ACAI). In this procedure, rate of fistula that results is reported in the literature between 15 and 25%. An alternative to ACAI is delayed coloanal anastomosis without reservoir (ACAD). Based on retrospective experiences, we form the hypothesis that ACAD offers a much lower rate of fistula (<5%) and allows diminution of preventive stoma derivation practice. Morbidity and mortality are reduced, and patient's quality of life greatly improved. Direct costs (consumables intraoperative, hospitalization, stoma complications) and indirect (pocket-fitting stoma) are greatly reduced. This study is a multicentre, two arms, phase 2 clinical trial.

Eligibility Criteria

Inclusion Criteria

  • Histologically proven rectal adenocarcinoma.
  • Medium or lower rectum tumour requiring removal of the entire rectum and its mesorectum.
  • T1 N+ or T2 N+ or T3 N+ or T3 N0 and M0 tumour.
  • Age between 18 and 75 years .
  • ASA ≤ 2.
  • Sphincter continence compatible with coloanal anastomosis.
  • Patients who received preoperative radiotherapy alone or chemotherapy and radiotherapy.
  • Patient affiliated to social security.
  • For patients of childbearing age, use of contraception.
  • Patient information and consent for study participation

Exclusion Criteria

  • Other histology of rectal cancer.
  • T1 N0 or T2 N0 or T4 tumour.
  • Metastatic disease M1.
  • History of cancer except cervix in situ carcinoma or skin basal cell carcinoma.
  • Patient with psychological, social, family or geographical reasons who couldn't be treated or monitored regularly by the criteria of the study
  • Patients deprived of liberty or under guardianship.
  • Pregnant or nursing women.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01876901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search